Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors
July 13, 2022 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
KRAS G12C Inhibitor Lumakras Sotorasib Drug Sales Forecast USD 1 Billion By 2028
July 07, 2022 06:04 ET
|
KuicK Research
Singapore, July 07, 2022 (GLOBE NEWSWIRE) -- "Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" Report Highlights: Global KRAS Inhibitors Market Opportunity: > USD 4 Billion...
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
June 28, 2022 07:00 ET
|
Revolution Medicines, Inc.
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise,...
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
June 09, 2022 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
May 09, 2022 16:02 ET
|
Revolution Medicines, Inc.
Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination...
Outlook on the KRAS Inhibitors Global Market to 2028 - Key Drivers and Challenges
April 27, 2022 05:28 ET
|
Research and Markets
Dublin, April 27, 2022 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com's offering. The advancement in...
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
April 21, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
March 09, 2022 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
March 01, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
February 28, 2022 16:05 ET
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in...